1. Ahmed AI, van Mierlo PJ, Jansen PA. Sleep disorders, nightmares, depression and anxiety in an elderly patient treated with low-dose metoprolol. Gen Hosp Psychiatry 2010; 32(6): 646.e5-7.
2.
Akimoto H, Tezuka K, Nishida Y, Nakayama T, Takahashi Y, Asai S. Association between use of oral hypoglycemic agents in Japanese patients with type 2 diabetes mellitus and risk of depression: A retrospective cohort study. Pharmacol Res Perspect 2019; 7(6): e00536.
3.
Anderberg R, Richard J, Hansson C, Nissbrandt H, Bergquist F, Skibicka K. GLP-1 Is Both Anxiogenic and Antidepressant; Divergent Effects of Acute and Chronic GLP-1 on Emotionality. Psychoneuroendocrinology 2016; 65: 54-66.
4.
Athauda D, Foltynie T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson’s disease: mechanisms of action. Drug Discov Today 2016; 21(5): 802-818.
5.
Aziz R, Steffens DC. What are the causes of late-life depression? Psychiatr Clin North Am 2013; 36(4): 497-516.
6.
Bai X, Liu Z, Li Z, Yan D. The association between insulin therapy and depression in patients with type 2 diabetes mellitus: a meta-analysis. BMJ Open 2018; 8(11): e020062.
7.
Banks WA, Owen JB, Erickson MA. Insulin in the brain: there and back again. Pharmacol Ther 2012; 136(1): 82‐93.
8.
Berge LI, Riise T, Tell GS, Iversen MM, Østbye T, Lund A, Knudsen AK. Depression in persons with diabetes by age and antidiabetic treatment: a cross-sectional analysis with data from the Hordaland Health Study. PLoS One 2015; 10(5): e0127161.
9.
Boal AH, Smith DJ, McCallum L, Muir S, Touyz RM, Dominiczak AF et al. Monotherapy With Major Antihypertensive Drug Classes and Risk of Hospital Admissions for Mood Disorders. Hypertension 2016; 68(5): 1132-1138.
10.
Cao YY, Xiang X, Song J, Tian YH, Wang MY, Wang XW et al. Distinct effects of antihypertensives on depression in the real-world setting. A retrospective cohort study. J Affect Disord 2019; 259: 386-391.
11.
Cha DS, Best MW, Bowie CR, Gallaugher LA, Woldeyohannes HO, Soczynska JK et al. A randomized, double-blind, placebo- controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder. J Affect Disord 2017; 210: 57-65.
12.
Chen F, Wei G, Wang Y, Liu T, Huang T, Wei Q et al. Risk factors for depression in elderly diabetic patients and the effect of metformin on the condition. BMC Public Health 2019; 19:1063.
13.
Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr. Cerebrospinal fluid and plasma insulin levels in Alzheimer’s disease: Relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998; 50(1): 164-168.
14.
Craft S, Baker LD, Montine TJ, Minoshima S, Stennis Watson G, Claxton A et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012; 69(1): 29-38.
15.
De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP et al. Protection of synapses against Alzheimer’s- linked toxins: Insulin signaling prevents the pathogenicbinding of Abeta oligomers. Proc Natl Acad Sci U S A 2009; 106(6): 1971-1976.
16.
Department of Economic and Social Affairs, United Nations. World Population Prospects: the 2019 Revision; https://population. un.org/wpp/ (last accessed on 28.02.2020).
17.
Diabetes Poland. 2020 Guidelines on the management of diabetic patients. A position of Diabetes Poland. Clin Diabetol 2020; 9, 1.
18.
Fan M, Cao T, Feng Y, Su M, Lin J, Ran MS et al. D allele of insertion/deletion polymorphism at angiotensin-converting enzyme gene is associated with reduced prevalence and severity of depression among Chinese adolescents at early stage after Wenchuan earthquake. Int J Psychiatry Clin Pract 2018; 22(2): 136-142.
19.
Forlani C, Morri M, Ferrari B, Dalmonte E, Menchetti M, De Ronchi D et al. Prevalence and gender differences in late-life depression: a population-based study. Am J Geriatr Psychiatry 2014; 22(4): 370-380.
20.
Gamble JM, Chibrikov E, Midodzi WK, Twells LK, Majumdar SR. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink. BMJ Open 2018; 8(10): e023830.
21.
Gong X, Hu H, Qiao Y, Xu P, Yang M, Dang R et al. The Involvement of Renin-Angiotensin System in Lipopolysaccharide- Induced Behavioral Changes, Neuroinflammation, and Disturbed Insulin Signaling. Front Pharmacol 2019; 10: 318.
22.
Grant P, Lipscomb D, Quin J. Psychological and quality of life changes in patients using GLP-1 analogues. Journal of Diabetes and Its Complications 2011; 25: 244-246.
23.
Grillo CA, Piroli GG, Kaigler KF, Wilson SP, Wilson MA, Reagan LP. Downregulation of hypothalamic insulin receptor expression elicits depressive-like behaviors in rats. Behav Brain Res 2011; 222(1): 230‐235.
24.
Grillo CA, Piroli GG, Lawrence RC, Wrighten SA, Green AJ, Wilson SP. Hippocampal Insulin Resistance Impairs Spatial Learning and Synaptic Plasticity. Diabetes 2015; 64(11): 3927‐3936.
25.
Guo M, Mi J, Jiang QM, Tang YY, Tian G, Wang B. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 2014; 41(9): 650-656.
26.
Hallschmid M, Benedict C, Schultes B, Born J, Kern W. Obese men respond to cognitive but not to catabolic brain insulin signaling. Int J Obes (Lond) 2008; 32(2): 275‐282.
27.
Hanson LR, Frey WH. Intranasal delivery bypasses the bloodbrain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008; 9(3): S5.
28.
He L, Sabet A, Djedjos S, Miller R, Sun X, Hussain MA et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 2009; 137: 635-646.
29.
Heppner KM, Kirigiti M, Secher A, Paulsen SJ, BuckinghamR, Pyke C et al. Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology 2015; 156(1): 255-267.
30.
Hunter K, Hölscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 2012; 13: 33.
31.
Iversen MM, Nefs G, Tell GS, Espehaug B, Midthjell K, Graue M et al. Anxiety, depression and timing of insulin treatment among people with type 2 diabetes: Nine-year follow-up of the Nord-Trøndelag Health Study, Norway. J Psychosom Res 2015; 79(4): 309‐315.
32.
Jackson L, Eldahshan W, Fagan SC, Ergul A. Within the Brain: The Renin Angiotensin System. Int J Mol Sci 2018; 19(3): 876.
33.
Jarskog LF, Hamer RM, Catellier DJ, Stewart DD, Lavange L,Ray N et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry 2013; 170(9): 1032-1040.
34.
Keshavarzi S, Kermanshahi S, Karami L, Motaghinejad M, Motevalian M, Sadr S. Protective role of metformin against methamphetamine induced anxiety, depression, cognition impairment and neurodegeneration in rat: The role of CREB/ BDNF and Akt/GSK3 signaling pathways. Neurotoxicology 2019; 72: 74-84.
35.
Kleinridders A, Cai W, Cappellucci L, Ghazarian A, Collins WR, Vienberg S et al. Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc Natl Acad Sci U S A. 2015; 112(11): 3463-3468.
36.
Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials [published correction appears in Lancet Diabetes Endocrinol. 2020 Mar; 8(3): e2]. Lancet Diabetes Endocrinol. 2019; 7(10): 776-785.
37.
Łabuzek K, Suchy D, Gabryel B, Bielecka A, Liber S, Okopień B. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccha-ride. Pharmacol. Rep. 2010; 62: 956-965.
38.
Lenart L, Balogh DB, Lenart N, Barczi A, Hosszu A, Farkas T et al. Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling. Diabetologia 2019; 62(8): 1501-1513.
39.
Liu D, Jin B, Chen W, Yun P. Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis. BMC Pharmacol Toxicol 2019; 20(1): 15.
40.
Lvijendijk HJ, van den Berg JF, Hofman A, Tiemeier H, Stricker BHC. β-Blockers and the Risk of Incident Depression in the Elderly. J Clin Psychopharmacol 2011; 31(1): 45-50.
41.
Lyra E, Silva NM, Lam MP, Soares CN, Munoz DP, MilevR, De Felice FG. Insulin Resistance as a Shared Pathogenic Mechanism Between Depression and Type 2 Diabetes. Front Psychiatry 2019; 10: 57.
42.
Ma TKW, Kam KKH, Yan BP and Lam Y. Renin-angiotensin-aldosterone System Blockade for Cardiovascular Diseases: Current Status. British Journal of Pharmacology 2010; 160: 1273-1292.
43.
Manaye KF, Lei DL, Tizabi Y, Dávila‐García MI, Mouton PR, Kelly PH. Selective neuron loss in the paraventricular nucleus of hypothalamus in patients suffering from major depression and bipolar disorder. J Neuropathol Exp Neurol 2005; 64: 224‐229.
44.
Mann SJ. Redefining beta-blocker use in hypertension: selecting the right beta-blocker and the right patient. J Am Soc Hypertens 2017; 11(1): 54-65.
45.
Mansur RB, Fries GR, Subramaniapillai M, Frangou S, De Felice FG, Rasgon N et al. Expression of dopamine signaling genes in the post-mortem brain of individuals with mental illnesses is moderated by body mass index and mediated by insulin signaling genes. J Psychiatr Res 2018; 107: 128‐135.
46.
Markowicz-Piasecka M, Sikora J, Szydłowska A, Skupień A, Mikiciuk-Olasik E, Huttunen KM. Metformin – a Future Therapy for Neurodegenerative Diseases: Theme: Drug Discovery, evelopment and Delivery in Alzheimer’s Disease Guest Editor: Davide Brambilla. Pharm Res 2017; 34(12): 2614-2627.
47.
Marks DR, Tucker K, Cavallin MA, Mast TG, Fadool DA. Awake intranasal insulin delivery modifies protein complexes and alters memory, anxiety, and olfactory behaviors. J Neurosci 2009; 29(20): 6734-6751.
48.
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017; 17(230).
49.
van Melle JP, Verbeek DE, van den Berg MP, Ormel J, van der Linde MR, de Jonge P. Beta-blockers and depression after myocardial infarction: a multicenter prospective study. J Am Coll Cardiol 2006; 48: 2209-2214.
50.
Mezuk B, Eaton WW, Albrecht S, Hill Golden S. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 2008; 31: 2383-2390.
51.
Nouwen A, Winkley K, Twisk J, Lloyd CE, Peyrot M, Ismail K et al. Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta analysis. Diabetologia 2010; 53: 2480-2486.
52.
Pavlatou MG, Mastorakos G, Lekakis I, Liatis S, Vamvakou G, Zoumakis E et al. Chronic administration of an angiotensin II receptor antagonist resets the hypothalamic-pituitary-adrenal (HPA) axis and improves the affect of patients with diabetes mellitus type 2: preliminary results. Stress 2008; 11(1): 62-72.
53.
Peters R, Yasar S, Anderson CS, Andrews S, Antikainen R, Arima H et al. Investigation of antihypertensive class, dementia, and cognitive decline: A meta-analysis. Neurology 2020; 94(3): e267-e281.
54.
Petrak F, Herpertz S, Stridde E, Pfützner A. Psychological insulin resistance in type 2 diabetes patients regarding oral antidiabetes treatment, subcutaneous insulin injections, or inhaled insulin. Diabetes Technol Ther 2013; 15(8): 703‐711.
55.
Pintana H, Apaijai N, Pratchayasakul W, Chattipakorn N, Chattipakorn SC. Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats. Life Sci 2012; 91(11-12): 409-414.
56.
Pomytkin I, Costa-Nunes JP, Kasatkin V, Veniaminova E, Demchenko A, Lyundup A et al. Insulin receptor in the brain: Mechanisms of activation and the role in the CNS pathology and treatment. CNS Neurosci Ther 2018; 24(9): 763‐774.
57.
Ranchord AM, Spertus JA, Buchanan DM, Gosch KL, Chan PS. Initiation of beta-blocker therapy and depression after acute myocardial infarction. Am Heart J 2016; 174: 37-42.
58.
Rhea EM, Banks WA. Role of the Blood-Brain Barrier in Central Nervous System Insulin Resistance. Front Neurosci 2019; 13: 521.
59.
Ribe EM, Lovestone S. Insulin signalling in Alzheimer’s disease and diabetes: From epidemiology tomolecular links. J Intern Med 2016; 280(5): 430-442.
60.
Ringoir L, Pedersen SS, Widdershoven JWMG, Pouwer F, Keyzer JML, Romeijnders AC, Pop VJM. Beta-blockers and Depression in Elderly Hypertension Patients in Primary Care. Fam Med 2014; 46(6):447-453.
61.
Ruegsegger GN, Manjunatha S, Summer P, Gopala S, Zabeilski P, Dasari S et al. Insulin deficiency and intranasal insulin alter brain mitochondrial function: a potential factor for dementia in diabetes. FASEB J 2019; 33(3): 4458-4472 (a).
62.
Ruegsegger GN, Vanderboom PM, Dasari S, Klaus KA, Kabiraj P, McCarthy CB et al. Exercise and metformin counteract altered mitochondrial function in the insulin-resistant brain. JCI Insight 2019; 4(18): e130681 (b).
63.
Saab YB, Gard PR, Yeoman MS, Mfarrej B, El-Moalem H,Ingram MJ. Renin-angiotensin-system gene polymorphisms and depression. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(5): 1113-1118.
64.
Salinero-Fort MA, Gómez-Campelo P, San Andrés-Rebollo FJ, Cárdenas-Valladolid J, Abánades-Herranz J, Carrillo de Santa Pau E et al. Prevalence of depression in patients with type 2 diabetes mellitus in Spain (the DIADEMA Study): results from the MADIABETES cohort. BMJ Open 2018; 8(9): e020768.
65.
Salive ME. Multimorbidity in older adults. Epidemiol Rev2013; 35: 75-83.
66.
Sharma AN, Ligade SS, Sharma JN, Shukla P, Elased KM, Lucot JB. GLP-1 receptor agonist liraglutide reverses long- -term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats. Metab Brain Dis 2015; 30: 519-527.
67.
Sinclair A, Morley JE, Rodriguez-Mañas L, Paolisso G, Bayer T, Zeyfang A et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc. 2012; 13(6): 497-502.
68.
Sinha S, Goldstein M, Penrod J, Hochman T, Kamran M, Tenner C et al. Brief Report: Beta-Blocker Use Among Veterans With Systolic Heart Failure. J Gen Intern Med 2006; 21(12): 1306-1309.
69.
Sjöberg L, Karlsson B, Atti AR, Skoog I, Fratiglioni L, Wang HX. Prevalence of depression: Comparisons of different depression definitions in population-based samples of older adults. J Affect Disord 2017; 221: 123-131.
70.
de Souza Gomes JA, de Souza GC, Berk M, Cavalcante LM, de Sousa GC, Budni J et al. Antimanic-like activity of candesartan in mice: Possible involvement of antioxidant, anti- inflammatory and neurotrophic mechanisms. Eur Neuropsychopharmacol 2015; 25(11): 2086-2097.
71.
Surwit RS, van Tilburg MA, Parekh PI, Lane JD, Feinglos MN. Treatment regimen determines the relationship between depression and glycemic control. Diabetes Res Clin Pract. 2005; 69(1): 78‐80.
72.
Tabák AG, Akbaraly TN, Batty GD, Kivimäki M. Depression and type 2 diabetes: a causal association? Lancet Diabetes Endocrinol 2014; 2: 236-245.
73.
Tanokashira D, Kurata E, Fukuokaya W, Kawabe K, Kashiwada M, Takeuchi H et al. Metformin treatment ameliorates diabetes-associated decline in hippocampal neurogenesis and memory via phosphorylation of insulin receptor substrate 1 [published correction appears in FEBS Open Bio. 2018 Oct 22; 8(11): 1882-1883]. FEBS Open Bio. 2018; 8(7): 1104-1118.
74.
Verbeek DEP, van Riezen J, de Boer RA, van Melle J, de Jonge P. A Review on the Putative Association Between Beta-Blockers and Depression. Heart Fail Clin 2011; 7(1): 89-99.
75.
Vian J, Pereira C, Chavarria V, Köhler C, Stubbs B, Quevedo J et al. The renin–angiotensin system: a possible new target for depression. BMC Medicine 2017; 15: 144.
76.
Wang CP, Lorenzo C, Habib SL, Jo B, Espinoza SE. Differential effects of metformin on age related comorbidities in older men with type 2 diabetes. Journal of Diabetes and Its Complications 2017; 31: 679-686.
77.
Wang F, Wang S, Zong QQ, Zhang Q, Ng CH, Ungvari GS et al. Prevalence of comorbid major depressive disorder in Type 2 diabetes: a meta-analysis of comparative and epidemiological studies. Diabet Med. 2019; 36(8): 961‐969.
78.
Wieczorowska-Tobis K. Specyfika pacjenta starszego. W: Fizjoterapia w geriatrii. Wieczorowska-Tobis K, Kostka T (red.), Wydawnictwo Lekarskie PZWL, Warszawa 2011, 18-28.
79.
Yarchoan M, Toledo JB, Lee EB, Arvanitakis Z, Kazi H, Han LY et al. Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer’s disease and tauopathies. Acta Nauropathol 2014; 128(5): 679-689.
80.
Zemdegs J, Martin H, Pintana H, Bullich S, Manta S, Marqués MA et al. Metformin Promotes Anxiolytic and Antidepressant- Like Responses in Insulin-Resistant Mice by Decreasing Circulating Branched-Chain Amino Acids. J Neurosci 2019; 39(30): 5935-5948.
81.
Zheng T, Qin L, Chen B, Hu X, Zhang X, Liu Y et al. Plasma Dipeptidyl Peptidase-4 Activity, a Novel Biomarker or Even a Possible Therapeutic Target for Depression in Type 2 Diabetic Patients: Results from a Cross-Sectional Study in China. Psychother Psychosom 2017; 86(4): 254-256.
82.
Zuliani I, Urbinati C, Valenti D, Quattrini MC, Medici V, Cosentino L et al. The Anti-Diabetic Drug Metformin Rescues Aberrant Mitochondrial Activity and Restrains Oxidative Stress in a Female Mouse Model of Rett Syndrome. J Clin Med 2020; 9(6): 1669.
